Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13188155 | 0.84 | HDAC4 (0.31) | CXCR3 | |
| Hydrochloric Acid SCHEMBL3707118 | 0.82 | CNR2 (0.30) | CNR2 | |
| SCHEMBL10058001 | 0.77 | ALDH1A1 (0.42) | CXCR3EPHA2EPHB4CNR2 | |
| SCHEMBL2831415 | 0.76 | AOC3 (0.35) | CXCR3 | |
| SCHEMBL21325031 | 0.76 | CXCR3 (0.31) | CXCR3 | |
| SCHEMBL4398054 | 0.76 | PIK3CG (0.35) | CXCR3 | |
| SCHEMBL22544835 | 0.76 | CXCR3 (0.31) | CXCR3EPHA2EPHB4 | |
| SCHEMBL21690696 | 0.76 | CXCR3 (0.31) | CXCR3 | |
| SCHEMBL478959 | 0.75 | CNR2 (0.33) | CXCR3EPHA2EPHB4CNR2 | |
| Hydrochloric Acid SCHEMBL3712851 | 0.74 | AOC3 (0.35) | CXCR3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| WO-2015051241-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CXCR3 1282/4885EPHA2 1751/4885EPHB4 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.